1
|
Who benefits from immunotherapy?
|
Allergy
|
1997
|
1.97
|
2
|
From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients.
|
Clin Pharmacol Ther
|
2015
|
1.59
|
3
|
The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation.
|
Exp Cell Res
|
2009
|
1.27
|
4
|
Methodology for development of the Allergic Rhinitis and its Impact on Asthma guideline 2008 update.
|
Allergy
|
2008
|
0.97
|
5
|
Nerve growth factor: neurotrophin or cytokine?
|
Int Arch Allergy Immunol
|
2003
|
0.96
|
6
|
Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application.
|
Int J Immunopharmacol
|
2000
|
0.95
|
7
|
Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers.
|
Ann Oncol
|
2010
|
0.92
|
8
|
Microfabricated biocapsules provide short-term immunoisolation of insulinoma xenografts.
|
Biomed Microdevices
|
1999
|
0.89
|
9
|
Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial.
|
Anticancer Res
|
1996
|
0.85
|
10
|
High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
|
Anticancer Res
|
1998
|
0.84
|
11
|
Rhinitis and asthma in athletes: an ARIA document in collaboration with GA2LEN.
|
Allergy
|
2006
|
0.84
|
12
|
Nerve growth factor and asthma.
|
Allergy
|
2002
|
0.83
|
13
|
Nonspecific provocation of target organs in allergic diseases: EAACI-GA(2)LEN consensus report.
|
Allergy
|
2007
|
0.81
|
14
|
Predictive value of allergy and pulmonary function tests for the diagnosis of asthma in elite athletes.
|
Allergy
|
2007
|
0.80
|
15
|
A new tumour associated antigen of non-small cell lung cancer: tumour liberated proteins (TLP)--a possible new tumor marker.
|
Anticancer Res
|
1996
|
0.79
|
16
|
Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a.
|
Eur J Cancer
|
1995
|
0.79
|
17
|
What we should learn from the London Olympics.
|
Curr Opin Allergy Clin Immunol
|
2013
|
0.79
|
18
|
The heterogeneity of allergic phenotypes: genetic and environmental interactions.
|
Ann Allergy Asthma Immunol
|
2001
|
0.79
|
19
|
Induction of apoptosis in neoplastic cells by anthracycline antitumor drugs: nuclear and cytoplasmic triggering?
|
Anticancer Res
|
1999
|
0.77
|
20
|
Combination therapy with BRMs in cancer and infectious diseases.
|
Mech Ageing Dev
|
1997
|
0.77
|
21
|
Diagnosis of asthma and permitted use of inhaled beta2-agonists in athletes.
|
Allergy
|
2004
|
0.77
|
22
|
Expression profile of saccharide epitope CaMBr1 in normal and neoplastic tissue from dogs, cats, and rats: implication for the development of human-derived cancer vaccines.
|
Histochem J
|
1999
|
0.77
|
23
|
Modifications of mitochondria in human tumor cells during anthracycline-induced apoptosis.
|
Anticancer Res
|
2000
|
0.76
|
24
|
Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice.
|
Int J Cancer
|
1992
|
0.76
|
25
|
Differential expression of a new tumor-associated antigen, TLP, during human colorectal cancer tumorigenesis.
|
Am J Pathol
|
1999
|
0.75
|
26
|
[Beta-glucronidase activity of granulocytes in patients with rheumatoid arthritis].
|
Boll Soc Ital Biol Sper
|
1975
|
0.75
|
27
|
Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery.
|
Cancer Immunol Immunother
|
1999
|
0.75
|
28
|
Atopic and vernal keratoconjunctivitis: a model for studying atopic disease.
|
Curr Probl Dermatol
|
1999
|
0.75
|
29
|
Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: clinical and immunological effects.
|
Ann Oncol
|
1995
|
0.75
|
30
|
Effectiveness of a new device to retain carcinogenic compounds of tar from mainstream cigarette smoke for the prevention of smoking-associated tumors.
|
Anticancer Res
|
2001
|
0.75
|
31
|
Cytoplasmic localization of anthracycline antitumor drugs conjugated with reduced glutathione: a possible correlation with multidrug resistance mechanisms.
|
Anticancer Res
|
1998
|
0.75
|
32
|
IgE in leprosy.
|
Int J Lepr Other Mycobact Dis
|
1982
|
0.75
|
33
|
IgE serum levels in urinary schistosomiasis.
|
Tropenmed Parasitol
|
1979
|
0.75
|